Bio-Rad Laboratories, Inc.
BIO
$241.07
-$12.08-4.77%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 108.94% | -209.59% | 130.16% | -664.08% | 9.77% |
| Total Depreciation and Amortization | -2.81% | 0.77% | 6.87% | -1.89% | -0.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -101.55% | 235.72% | -125.78% | 817.23% | -36.10% |
| Change in Net Operating Assets | 120.19% | -197.87% | 132.48% | -1,358.33% | 758.54% |
| Cash from Operations | 4.59% | -24.07% | 67.51% | 39.89% | -13.83% |
| Capital Expenditure | 19.84% | -6.67% | 4.85% | -5.18% | 4.89% |
| Sale of Property, Plant, and Equipment | -- | -185.96% | -13.64% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 200.35% | 180.31% | -237.00% | 489.24% | -102.59% |
| Cash from Investing | 109.49% | 45.10% | -79.89% | 28.24% | -159.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -143.90% | 66.67% | -4.24% | 41.00% | -32.45% |
| Issuance of Common Stock | 9.97% | -23.36% | 8.95% | -14.85% | 26.96% |
| Repurchase of Common Stock | -75,944.78% | 99.87% | 0.18% | -2,052.17% | 97.70% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | -272.22% | 72.65% | 0.62% | -- | 100.00% |
| Foreign Exchange rate Adjustments | -117.61% | 236.01% | -296.16% | 41.89% | 141.60% |
| Miscellaneous Cash Flow Adjustments | -- | -200.00% | -- | -- | -- |
| Net Change in Cash | -57.08% | 1,634.43% | 117.18% | -188.56% | 154.57% |